CLINICAL TRIALS PROFILE FOR LOTEPREDNOL ETABONATE
✉ Email this page to a colleague
All Clinical Trials for LOTEPREDNOL ETABONATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00366691 ↗ | Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation | Completed | Medical University of South Carolina | Phase 4 | 2006-02-01 | The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery. |
| NCT00420628 ↗ | Pediatric Zylet Safety and Efficacy Study | Completed | Bausch & Lomb Incorporated | Phase 4 | 2006-11-01 | A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum) |
| NCT00447577 ↗ | Zylet vs TobraDex in Blepharokeratoconjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 4 | 2007-01-01 | The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis |
| NCT00560638 ↗ | Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye | Completed | Bausch & Lomb Incorporated | Phase 2 | 2005-11-01 | This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization. |
| NCT00645671 ↗ | Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery | Completed | Bausch & Lomb Incorporated | Phase 3 | 2008-03-01 | To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery |
| NCT00689078 ↗ | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model | Completed | ORA, Inc. | Phase 4 | 2008-05-01 | To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID) dosing and 1 week of four times daily (QID) dosing. |
| NCT00699153 ↗ | Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery | Completed | Bausch & Lomb Incorporated | Phase 3 | 2008-06-01 | Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOTEPREDNOL ETABONATE
Condition Name
Clinical Trial Locations for LOTEPREDNOL ETABONATE
Trials by Country
Clinical Trial Progress for LOTEPREDNOL ETABONATE
Clinical Trial Phase
Clinical Trial Sponsors for LOTEPREDNOL ETABONATE
Sponsor Name
